Here, we hypothesized that combining menin inhibitors with other epigenetic-modifying drugs would synergistically disrupt leukemogenic transcriptional programs and enforce stable differentiation, thereby yielding more durable therapeutic responses in MLL-r AML. The gene discussed is KMT2A; the disease is acute myeloid leukemia.